Starting clozapine in patients with schizophrenia during the ongoing pandemic.

Grover, Sandeep; Naskar, Chandrima; Sahoo, Swapnajeet; Mehra, Aseem; Chakrabarti, Subho

Grover, Sandeep; Naskar, Chandrima; Sahoo, Swapnajeet; Mehra, Aseem; Chakrabarti, Subho.

Afiliação

Grover S; Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India. Electronic address: drsandeepg2002@yahoo.com.
Naskar C; Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
Sahoo S; Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
Mehra A; Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
Chakrabarti S; Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.

Schizophr Res ; 243: 440-442, 2022 05.

Article em En | MEDLINE | ID: mdl-34303594

Assuntos

Antipsicóticos; Clozapina; Esquizofrenia; Antipsicóticos/uso terapêutico; Clozapina/uso terapêutico; Humanos; Estudos Longitudinais; Pandemias; Esquizofrenia/tratamento farmacológico; Esquizofrenia/epidemiologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Clozapina Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google